Rigel Downsizes R&D To Ready Fostamatinib Commercial Effort

Biotech will cut 46 staff, mostly in research, including the entire antibody group, to focus on commercializing its Phase III thrombocytopenia candidate fostamatinib. Rigel adds industry vet Eldon Mayer to head up commercial team.

About two weeks after announcing success in the first Phase III trial of its platelet drug fostamatinib in chronic/persistent immune thrombocytopenia, Rigel Pharmaceuticals Inc. announced a 38% staff reduction, more or less gutting its R&D division to add a nearly equivalent headcount in commercial personnel.

As part of the Sept. 15 announcement, Rigel reported the retirement of board member and Executive VP of Discovery and...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immunological

More from Therapeutic Category